Journal
DRUG DISCOVERY TODAY
Volume 28, Issue 2, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2022.103440
Keywords
immunology; immuno-oncology; biotherapeutics; nonclinical assessment
Categories
Ask authors/readers for more resources
Harnessing the immune system to kill tumors has revolutionized cancer treatment, but it can also lead to adverse events that pose safety risks. This article reviews the biology and mechanisms of immune-mediated adverse effects and discusses industry approaches for nonclinical safety risk assessments in immune-oncology.
Harnessing the immune system to kill tumors has been revolutionary and, as a result, has had an enormous benefit for patients in extending life and resulting in effective cures in some. However, activation of the immune system can come at the cost of undesirable adverse events such as cytokine release syndrome, immune-related adverse events, on-target/off-tumor toxicity, neurotoxicity and tumor lysis syndrome, which are safety risks that can be challenging to assess non-clinically. This article provides a review of the biology and mechanisms that can result in immune-mediated adverse effects and describes industry approaches using in vitro and in vivo models to aid in the nonclinical safety risk assessments for immune-oncology modalities. Challenges and limitations of knowledge and models are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available